Biomarker Bulletin: June 20, 2011

Reading time: 2 – 4 minutes

Biomarker Bulletin is an occasionally recurring update of news focused on biomarkers aggregated at Biomarkers are physical, functional or biochemical indicators of normal physiological or disease processes. The individualization of disease management — personalized medicine — is dependent on developing biomarkers that promote specific clinical domains, including early detection, risk, diagnosis, prognosis and predicted response to therapy.

Biomarker Commons

  • Results of Highly Cited Biomarker-disease Associations Often Overestimated

    Although new biomarkers are regularly proposed to serve as potential determinants of disease risk, prognosis or response to treatment, many markers only get evaluated in one or a small number of studies. A review in the June 1st edition of JAMA reports that the results of highly cited biomarker-disease associations that appear in major journals are often substantially overestimated, with effect sizes exceeding those found when the association is evaluated in larger studies.

  • Roche, UCLA Announce Biomarker Research Collaboration

    Roche said last week that it will provide UCLA scientists with a range of genomics tools as part of a research collaboration to study stem cells and cancer, and for the development of new predictive biomarkers for future therapeutics and diagnostics for a host of diseases.

  • Stemina Biomarker Discovery, Children’s Hospital of Orange County Sign Agreement to Study Autism

    Stemina Biomarker Discovery announced on Friday that it has signed an agreement with Children’s Hospital of Orange County (CHOC) to conduct a study of neural cells from autistic patients using Stemina’s proprietary biomarker discovery platform.

  • Indiana CTSI, GVK Biosciences Partner to Provide National Access to Biomarkers Database

    The Indiana Clinical and Translational Sciences Institute (CTSI), a statewide collaboration of Indiana University, Purdue University and the University of Notre Dame, as well as public and private partnerships, which facilitates the translation of scientific discoveries in the lab into clinical trials and new patient treatments in Indiana and beyond, announced on Friday that they have partnered with GVK Biosciences. GVK Biosciences will provide researchers across the United States access to their clinical biomarker database.

  • Biomarker Briefs: June 13, 2011

    Biomarker Briefs is an occasionally recurring series highlighting particularly interesting articles on biomarkers and/or personalized medicine. This edition includes articles on personalized medicine, a new online tool for analyzing personal genome data, a blood test for depression, and a kidney injury biomarker initiative.

About the Author

Walter Jessen, Ph.D. is a Data Scientist, Digital Biologist, and Knowledge Engineer. His primary focus is to build and support expert systems, including AI (artificial intelligence) and user-generated platforms, and to identify and develop methods to capture, organize, integrate, and make accessible company knowledge. His research interests include disease biology modeling and biomarker identification. He is also a Principal at Highlight Health Media, which publishes Highlight HEALTH, and lead writer at Highlight HEALTH.